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ABSTRACT
Objectives: It is the prospective observational study aimed at early prediction of pregnancy complications in women with 
symptoms of MS.
Material and methods: 124 Caucasian women in singleton pregnancies 11th to the 13th wks 6 days of gestation with MS 
criteria compared to 30 healthy controls. Perinatal maternal and fetal results were analyzed.
Results: Increased in the MS group were: age (32.9 y vs. 28.6 y; p = 0,00), weight 11 to 13 + 6 weeks of gestation (79.0 kg 
vs. 59.7 kg; p = 0.00), BMI (29 kg/m2 vs. 21.6 kg/m2; p = 0.00), waist–hip ratio (WHR) (0.9 vs. 0.8; p = 0.00). Maternal serum param-
eters were higher in the MS group: LDL-cholesterol (124.1 vs. 109.6 mg/dL; p = 0.02), t-PA (2556.8 vs. 1949.5 pg/mL; p < 0.00), 
GGTP (16.8 vs. 13.3 IU/L; p = 0.02) and lower values for: adiponectin (6.4 vs. 7.5 µg/mL; p = 0.01), SHBG (273.4 vs. 338.4 nmol/L; 
p = 0.001). MS group neonates higher body weight (3594.4 vs. 3312.2 g; p = 0.01), significantly frequent macrosomic neo-
nates (> 4000 g) (20.9% vs. 6.6%; p = 0.042), GDM (12% vs. 0; p = 0.019).
Conclusions: Higher E-selectin serum concentration, GGTP and lower SHBG in the first trimester are additionally to fast-
ing maternal glucose, higher BMI and maternal age predictive for GDM. Higher E-selectin, fasting glucose, increased BMI 
and lower adiponectin serum concentration in the first trimester are significant predictors of fetal macrosomia. Maternal 
BMI > 24.5 kg/m2 is the best predictor of increased risk of fetal macrosomia and gestational diabetes mellitus.
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INTRODUCTION
In 2005, the World Health Organization (WHO) estimated 
that at least 400 million adults were obese (defined as hav-
ing a body mass index [BMI] > 30 kg/m2), and that this 
figure is projected to rise to over 700 million by 2015 [1]. 
Obesity among pregnant women is highly prevalent and is 
associated with an increased risk of adverse outcomes for 
mother and infant [2]. Epidemiological studies in Poland 
confirm this global phenomenon of a growing number of 
obese adults. The largest studies show that 28–29% women 
are overweight (BMI 25.0–29.9 kg/m2), and 19–22% are 
obese (BMI > 30 kg/m2) [3–4]. Increased BMI is a major de-
terminant of pregnancy outcome, and maternal obesity is 
associated with increased risk of the majority of pregnancy 
complications, including maternal complications such as 
gestational diabetes mellitus (GDM), gestational hyperten-
sion (GH), preeclampsia (PE), venous thromboembolism 
(VT), increased cesarean delivery rate. Furthermore, fetal 
complications are more likely, including small for gestational 
age (SGA), intrauterine growth restriction (IUGR), macroso-
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mia and stillbirth [2, 4]. Maternal metabolic disturbances, 
such as increased blood pressure, decreased insulin sen-
sitivity and elevated plasma lipids are accelerated during 
pregnancy, secondary to the increased metabolic needs of 
the placenta and fetus [5–6]. Levels of serum adiponectin, 
an adipocytokine released from adipose tissue, are inversely 
correlated with insulin resistance, and its reduced concen-
tration is apparent from the first trimester of pregnancy. It 
is possible, that serum adiponectin may be a biomarker of 
metabolic derangement observed in obesity and GDM [7]. 
Additionally, fat tissue is responsible for the chronic inflam-
matory response, which in pregnancy can lead to endothe-
lial dysfunction, a potential cause of preeclampsia [8]. The 
expression of the adhesion molecule E-selectin is tightly 
regulated by the inflammatory response: soluble forms are 
released into the circulation and may indicate endothelial 
dysfunction. Consequently, it is considered to be a potential 
marker of preeclampsia [8].
The aim of this study was to evaluate metabolic syn-
drome (MS) exponents in pregnant women in the first tri-
mester of gestation to find and confirm any correlation with 
perinatal complications.
MATERIAL AND METHODS
This was a prospective observational study aimed at 
the early prediction of pregnancy complications in women 
with symptoms of MS. The study was conducted between 
2011 and 2013. During routine visits in pregnancy, held 
between the 11th to the 13th weeks and 6 days of gestation, 
we recorded maternal characteristics, anthropometric data, 
and medical history and we performed combined screening 
for aneuploidies. The population comprised 127 Cauca-
sian women in singleton pregnancies who fulfilled criteria 
for MS. These criteria included the presence of any 3 of 5 risk 
factors: population-specific elevated waist circumference; 
elevated triglycerides (drug treatment for elevated triglyc-
erides is an alternate indicator) ≥ 150 mg/dL; reduced high 
density lipoprotein cholesterol (HDL-C) (drug treatment 
for reduced HDL-C is an alternate indicator) < 40 mg/dL 
(1.0 mmol/L) in males and < 50 mg/dL (1.3 mmol/L) in fe-
males; elevated blood pressure (antihypertensive drug treat-
ment in a patient with a history of hypertension is an alter-
nate indicator) systolic ≥ 130 and/or diastolic ≥ 85 mm Hg; 
and, elevated fasting glucose (drug treatment of elevated 
glucose is an alternate indicator) ≥ 100 mg/dL [9]. The control 
group comprised 30 women with health pregnancies. For 
the final analysis, we included 124 women and 30 controls 
who completed informed, written consent. 
At designated pregnancy visits (11–13 ± 6 weeks) blood 
samples were taken after overnight fasting and transported 
to the certificated Vitalabo Labolatory Diagnostics in Toruń 
the same day following biological specimen regulations in 
cooling conditions 2–8°C. Analysis of delivered material was 
performed on the same day. HDL-C, triglicerides (TG), total 
cholesterol (CH) and additional parameters including: tissue 
plasminogen activator (t-PA), sex-hormone binding globulin 
(SHBG) and gamma glutamyl transpeptidase (GGTP) were 
measured as biomarkers for MS (Roche Diagnostics reagents 
on a Cobas c501 analyzer). The following formula was used to 
calculate the level of low density lipoprotein (LDL) cholesterol: 
LDL cholesterol = total cholesterol – HDL cholesterol – (TG/5). 
The standard oral glucose tolerance test (OGTT) was performed 
in the MS group in the first trimester and if GDM was excluded 
this test was repeated in the second trimester of pregnancy 
with 75 g of glucose at 24–28 weeks of pregnancy, accord-
ing to Polish Gynecology Society Recommendations [10]. 
In the control group, the OGTT was performed in the second 
trimester, between the 24–28th week. Gestational hyperten-
sion was noted if systolic blood pressure was above 140 or 
diastolic was above 90 mm Hg, and the patient had pre-
eclampsia with the presence of proteinuria above 300 mg/d. 
In all participants, at the same time, blood was also drawn 
for assessment of serum adiponectin and E-selectin con-
centrations. Blood samples were centrifuged, aliquoted and 
stored at –80oC until assayed in the Department of Pediatric 
Gastroenterology and Metabolic Diseases Clinic, University 
of Medical Science in Poznan, using commercially available 
ELISA kits (R & D Systems, Minneapolis, USA). Anthropometric 
measurements (height, weight, and waist/hip circumference) 
and blood pressure measurements were performed at the 
onset of the study. 
Large-for-gestational age (LGA) was defined as birth 
weight greater than the 90th percentile using age- and 
sex-specific regional growth charts. Small-for-gestational 
(SGA) was defined as birth weight smaller than 10th centile 
on the same charts.
The study protocol was approved by University of Medi-
cal Science in Poznań Ethics Committee no 284/11.
Statistical analysis
Statistical analysis of the obtained data was performed 
using the original statistical package modules of Statis-
tica 10 (Statsoft Inc.). Variable distribution was assessed 
with the Shapiro-Wilk test. Comparison of unpaired quan-
titative variables was performed with the Student t-test 
or Cochrane-Cox test, depending on the distribution of 
data. In the case of non-normally distributed data, compari-
sons were made using the Mann-Whitney U test and the 
Chi-squared test was used for the comparison of categorical 
variables with Yates’s correction for continuity due to the 
low case count < 5. Statistical significance was defined as 
p < 0.05. The detection rate of adverse outcomes in preg-
nancy, in addition to other analyses, was determined by the 
receiver operating curve (ROC) analysis.
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RESULTS
Maternal anthropometric characteristics in the MS and 
control groups are compared in Table 1. The following vari-
ables were significantly different between the MS and the 
control group: patient age (32.9 years vs. 28.6 years; p = 0.00), 
weight in the 11th to 13th (± 6 days) weeks of gestation 
(79.0 kg vs. 59.7 kg; p = 0.00), BMI (29 kg/m2 vs. 21.6kg/m2; 
p = 0.00), and waist-hip ratio (WHR) (0.9 vs. 0.8; p = 0.00). 
Other variables, measured in the first trimester of pregnancy, 
including maternal weight gain during pregnancy, height, 
arterial blood pressure, both systolic and diastolic, showed 
no significant difference between the groups. 
The maternal serum parameters measured in the first 
trimester of pregnancy in patients with MS and in the con-
trol group are compared in Table 2. The following variables 
are significantly higher in the MS group: LDL-cholesterol 
(124.1 vs. 109.6 mg/dL; p = 0.02), t-PA (2556.8 vs. 1949.5 pg/mL; 
p < 0.00), and GGTP (16.8 vs. 13.3 IU/L; p = 0.02). Statistical ana- 
lysis showed significantly lower values of the following parame-
ters in MS patients compared to the control group: adiponectin 
(6.4 vs. 7.5 µg/mL; p = 0.01) and SHBG (273.4 vs. 338.4 nmol/L; 
p = 0.001). Levels of E-selectin and fasting glucose were not 
significantly different between the groups. 
Prospective analysis of maternal and fetal pregnancy 
outcomes in cases with MS and in controls is shown in 
Table  3. MS patients delivered neonates of significantly 
higher body weight (3594.4 g vs. 3312.2 g; p = 0.01). The 
number of macrosomic neonates (> 4000 g) was also higher 
in the MS group (20.9% vs. 6.6%; p = 0.042) as well as the 
incidence of GDM (12% vs. 0%; p = 0.019). The number of 
caesarean sections, LGA- and SGA- newborns, cases with 
gestational hypertension, PE and preterm delivery showed 
no differences between the MS group and control group. No 
patients with VT were observed in either group.
First trimester maternal parameters in women who 
developed GDM and those who did not are presented in 
Table 4. GDM patients were significantly older, presented in 
the first trimester with a significantly higher BMI, had higher 
concentration of fasting glucose, GGTP and E-selectin, and 
had a lower concentration of SHBG compared to patients 
without GDM. Serum adiponectin levels did not differ be-
tween the groups. 
The maternal characteristics and biochemical profile of 
women who delivered macrosomic babies are presented in Ta-
ble 5. In the pregnancies with macrosomia (n = 28) compared 
to those who delivered eutrophic neonates, the following vari-
ables were higher: BMI (28.0 vs. 22.0 kg/m2; p < 0.001), mater-
nal weight in the first trimester of pregnancy (77.9 vs. 60.8 kg; 
p < 0.001), fasting glucose (87.2 vs. 82.1 mg/dL; p < 0.042) 
and E-selectin concentration (32.1 vs. 24.5 ng/mL; p = 0.01). 
Table 1. Maternal anthropometric characteristics of the MS and of the control group
Variable
MS group
(n = 124)
Control group
(n = 30) P
x MIN MAX SD x MIN MAX SD
Age (years) 32.9 20.0 43.0 5.0 28.6 22.0 40.0 4.0 0.00**
I trimester weight [kg] 79.0 52.0 126.0 11.9 59.7 46.0 76.0 6.7 0.00*
I trimester BMI [kg/m2] 29.0 19.2 47.0 4.2 21.6 16.5 24.5 2.4 0.00**
WHR 0.9 0.7 1.0 0.1 0.8 0.7 1.0 0.1 0.00**
*Cochrane-Cox test; **Mann-Whitney test; x — median; SD — standard deviation 
Table 2. Maternal serum adiponectin, E-selectin and metabolic syndrome markers in the MS and in the control group
Variable
MS group
(n = 124)
Control group
(n = 30) p
x MIN MAX SD x MIN MAX SD
LDL cholesterol [mg/dL] 124.1 70.5 280.5 30.2 109.6 76.2 162.7 23.4 0.015*
Fasting glucose [mg/dL] 85.6 70.1 142.9 8.2 82.4 66.2 97.6 6.2 0.05**
t-PA [pg/ml] 2556.8 353.5 10000.0 1148.4 1949.5 935.5 6751.3 1027.6 < 0.00**
GGTP [lU/l] 16.8 5.0 87.0 12.8 13.3 5.6 76.0 12.3 0.02**
Adiponectin [µg/mL] 6.4 1.8 26.3 3.4 7.5 2.4 12.6 2.7 0.01**
E-selectin [ng/mL] 28.9 11.0 59.0 11.2 24.7 12.0 41.0 8.3 0.09**
SHGB [nmol/L] 273.4 68.3 706.1 97.4 338.4 168.0 521.3 92.0 0.001*
*t-Student test; ** Mann-Whitney test; x — median; SD — standard deviation 
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Table 3. Maternal and fetal outcome in MS and in the control group
Parameters MS group(n = 124)
Control group 
(n = 30) p
Neonatal weight [g]
x 3594.4 x 3312.2
0.01***
min 560 min 1460.0
max 5130 max 4450.0
SD 637.0 SD 544.5
Cesarean section (N, %) 43 (34.7) 8 (26.7) 0.403*
Preterm delivery < 37 wks (N, %) 4 (3.2) 1 (3.3) 0.582**
Neonatal weight > 4000 g (N, %) 26 (20.9) 2 (6.6) 0.0422*
LGA > 90 percentile (N, %) 16 (12.9) 2 (6.6) 0.524**
SGA < 10 percentile (N, %) 5 (4.0) 1 (3.3) 0.747**
GDM (N, %) 12 (9.6 ) 0 0.019*
Gestational hypertension (N, %) 7 (5.6) 1 (3.3) 0.957**
PE (N, %) 1 (0.8) 0 0.439**
*χ2 test; **χ2 test with Yates correction; ***Mann-Whitney test; x — mean; SD —standard deviation; N — number of cases
Table 4. Maternal characteristics and biochemical parameters in the first trimester in patients who developed GDM
Variable
GDM group 
(n = 19)
Non-GDM group 
(n = 135) p*
x MIN MAX SD x MIN MAX SD
Age (years) 34.7 30.0 43.0 3.9 28.7 20.0 40.0 4.3 < 0.01
I trimester BMI [kg/m2] 31.6 24.2 47.0 7.4 21.8 16.5 30.8 2.9 < 0.00
Fasting glucose [mg/dL] 104.2 95.2 142.9 15.1 82.4 66.2 92.1 5.7 < 0.00
Adiponectin [µg/mL] 6.0 3.5 11.3 2.5 8.3 2.4 26.3 4.3 0.07
GGTP [IU/l] 24.7 7.3 87.0 22.6 12.9 5.0 76.0 12.4 < 0.03
E-selectin [ng/mL] 32.3 16.0 59.0 10.5 24.7 11.0 41.0 8.3 < 0.04
SHGB [nmol/L] 249.0 68.3 396.8 100.3 338.4 168.0 521.3 92.0 < 0.02
*Mann-Whitney test; x — mean; SD — standard deviation 
Table 5. Maternal characterstics and biochemical analysis in the first trimester of pregnancy that delivered macrosomic neonates
Variable
Macrosomia (> 4000 g)
(n = 28)
Non-macrosomia
(n = 126) p*
x MIN MAX SD x MIN MAX SD
Maternal weight (11–14 wks) [kg] 77.9 58.0 126.0 14.7 60.8 46.0 86.0 8.42 < 0.001
Maternal BMI [kg/m2] 28.0 20.5 47 5.4 22.0 16.5 30.5 2.9 < 0.001
Fasting glucose [mg/dL] 87.2 70.1 142.9 12.9 82.1 66.2 97.6 6.3 < 0.042
Adiponectin [µg/mL] 5.6 3.2 7.7 1.5 9.1 4.7 26.3 3.9 < 0.001
E-selectin [ng/mL] 32.1 12.0 59.0 10.8 24.5 11.0 43.0 8.3 0.01
*Mann-Whitney test; x — mean; SD — standard deviation
Adiponectin serum levels were significantly lower in the 
macrosomic group compared to the eutrophic group 
(5.6 vs. 9.1 µg/mL; p < 0.001).
The main aim of this study was to identify any parameters 
that may have the best predictive value for an adverse preg-
nancy outcome. The ROC for all parameters that had an area 
under the curve (AUC) above 0.7, are presented in Table 6. The 
best predictive value for adverse outcomes in pregnancy 
was associated with GDM, GH, LGA and macrosomia, and 
BMI > 24.5kg/m2 (0.943, 0.925, 0.927 and 0.911) (Tab. 7).
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DISCUSSION
MS is a cluster of interrelated metabolic factors such as 
insulin resistance, hyperinsulinemia, abdominal obesity, im-
paired glucose tolerance, dyslipidemia, and hypertension, 
in the context of a proinflammatory and prothrombotic 
state [11]. Our results confirm that patients with MS have 
significantly increased BMI, and significantly increased inci-
dence of GDM compared to patients without MS. Our data 
did not confirm observations regarding other pregnancy 
adverse outcomes as published in the research literature. 
For instance, Beaten et al. suggested, that obese and over-
weight women had a consistent increase not only in the 
frequency of GDM, but also PE and eclampsia in comparison 
to women with a BMI of less than 20 kg/m2 [12]. Sebire 
et al. also confirmed an increased risk of GDM, PE, LGA 
and caesarean sections, but surprisingly decreased risk 
of preterm delivery, in group of pregnant women with 
a BMI > 25kg/ m2 [13]. 
There are studies suggesting that there is an increased 
risk of preterm delivery in MS patients associated with low 
levels of serum adiponectin [14]. In our study, decreased se-
rum adiponectin in the MS group was observed, but a small 
number of cases with preterm delivery did not confirm pre-
vious study findings. Another adverse pregnancy outcome 
we have observed in our study was GDM. According to 
Wójcikowski et al., the prevalence of GDM in Polish popula-
tion is 2–3.8%, depending on the region [15]. However, fol-
lowing publication of this study, new criteria for GDM were 
established and accordingly the incidence of GDM in the Pol-
ish population may be different. In our study, the prevalence 
of GDM was 9.6% in women with a BMI > 25 kg/m2. The BMI 
cut-off value, above which the risk of GDM was significant-
ly increased, was 24.5 kg/m2. Ogonowski et al. suggested 
that the risk of GDM is significantly higher in patients with 
a BMI > 22.85 kg/m2. This is the only paper published that 
suggests such low cut-off of BMI as a risk factor for GDM [16]. 
Lacroix et al. published data showing significantly decreased 
serum adiponectin levels in the first trimester of pregnancy 
in patients who later developed GDM [17]. Our data con-
firmed this observation. We also observed in the MS group 
of patients an increased prevalence of GDM and lower serum 
adiponectin levels in the first trimester of pregnancy, in 
comparison to patients without MS. The likely mechanism 
underlying a lower adiponectin serum concentration and 
the presence of GDM is increased insulin resistance and 
glucose intolerance. Similar observations have been noted 
by Nanda et al., who researched pregnant women delivering 
macrosomic neonates [7]. 
Table 6. AUROC values for measured paremeters in pregnancy complication prediction
AUC
Pregnancy complication
GDM GH LGA Macrosomia SGA Cesarean section
Waist circumference 0.738 – – – 0.836 0.706
Body weight in I trimester 0.925 0.942 0.914 0.894 0.863 0.773
Weight gain – – – 0.739 – –
RR systolic – 0.777 – – – –
WHR – – 0.713 – – 0.732
Age 0.858 – – – 0.790 –
Adiponectin – – – 0.875 – –
E-selectin 0.708 – – – – –
Total cholesterol -– 0.798 – – – –
SHBG 0.736 – – – – –
Fasting glucose 0.894 – – – – –
t-PA – 0.742 – – – –
Table 7. Receiver operator curve BMI values summary for pregnancy adverse outcomes
Pregnancy complications
BMI
AUC Sensitivity Specificity Cut-off
GDM 0.943 0.917 0.833 24.5
GH 0.925 0.875 0.800 24.5
LGA 0.927 0.880 0.933 25.5
Macrosomia 0.911 0.833 0.933 25.5
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In the GDM group, we also confirmed the possible role 
of SHBG as a marker of liver response to insulin, as well as of 
insulin resistance, manifested by increased GGTP levels. This 
finding is consistent with data collected by Kavanagh et al., 
who also observed lower SHBG in obese women [18]. In 
our study, we also noticed a significantly decreased SHBG 
concentration in patients with GDM in comparison to the 
non-GDM group.
What is also important, recent reports show, is that undia- 
gnosed GDM increases the risk of certain maternal and fetal 
complications, including pregnancy-induced hypertension, 
PE, macrosomy, stillbirth, miscarriage and fetal anomalies, 
especially in the central nervous system [19–21]. It has been 
reported that t-PA has a mitogenic role in smooth muscle cells, 
suggesting that its overproduction may contribute to vascular 
damage, although it may also favour atherogenesis. Hyper-
triglyceridemia has been observed in patients with PE, which 
may compromise endothelial cell function and thus may 
favour thrombosis and atherosclerosis [22]. Belo et al. noticed 
that increased serum t-PA levels were present in the third 
trimester of pregnancy in women with PE [22]. In our study, 
we also observed higher t-PA levels in the first trimester in the 
MS group, but due to small number of PE cases we could not 
confirm its predictive role for this complication. 
Our results reinforce the observation of fetal excessive 
weight gain in obese patients. We found a significantly in-
creased number of neonates weighing more than 4000 g in 
the MS group in comparison to the group with MS. The BMI 
cut-off value for LGA and macrosomia was 24.5 kg/m2. One of 
the parameters that differed between these two study groups 
was the concentration of LDL-cholesterol. The pathogenesis 
of that phenomenon is uncertain, however Freinkel et al. 
suggested that excessive fetal weight may be caused by 
increased transplacental lipid transport related to maternal 
hyperlipidemia [23]. 
In our study, due to the small number of patients with PE, 
we were not able to evaluate the role of E-selectin in the 
pathogenesis of PE. However, recent data suggest that E-se-
lectin plays important role in the development of PE [8]. We 
observed an increased serum E- selectin concentration in pa-
tients with GDM in comparison to those without GDM. These 
observations differ from those made by Zawiejska et al., 
who examined patients with pregestational diabetes mel-
litus, and reported lower E-selectin levels in this group [24]. 
In our opinion these opposing results might be related to 
the longer period of endothelial injury caused by metabolic 
disturbances in pregestational diabetes mellitus. 
CONCLUSIONS
1. Higher E-selectin serum concentration, GGTP and lower 
SHBG in the first trimester, in addition to fasting mater-
nal glucose, higher BMI and maternal age, are predictive 
for GDM.
2. Higher E-selectin, fasting glucose, BMI levels, and lower 
adiponectin serum concentrations in the first trimester 
are significant predictors of fetal macrosomia.
3. Maternal BMI > 24.5 kg/m2 is the best predictor of an in-
creased risk of fetal macrosomia and GDM, based on all 
of the measured parameters. 
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